News|Articles|May 28, 2024
Accelerating Therapies With Curia From Conception to Manufacturing
Author(s)Curia
Partnering with a CDMO can help streamline drug development, and certain preparations can help ensure a successful collaboration. Scott Alderucci, Curia’s Director of Process Development, explores the advantages of partnering with a CDMO to navigate the journey from molecule conception to clinical trials, including the expertise, experience, and preparedness that a CDMO brings to the table.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
